Description
Phase
Phase 2 - takes the treatment one step further, assessing the activity of a particular therapy in a disease, often building upon leads from the Phase I trial. While patients are generally required to be previously untreated, participation in a Phase II trial doesn't usually preclude the patient from getting the standard treatment after they've received the investigational agent. At best they are allowed to get a new drug they wouldn't be able to get otherwise that may turn out to be better for their disease.Inclusion and Exclusion Criteria
Please contact the trial administrator to learn more about the eligibility criteria for this trial. Please use the contact form on the right side.
Sites
-
California
- USC/Norris Comprehensive Cancer Center, Los Angeles, California, 90033
- The Angeles Clinic and Research Institute, Los Angeles, California, 90025
- Breastlink Medical Group, Long Beach, California, 90806
- UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, 94143
-
Montana
- Montana Cancer Institute Foundation, Missoula, Montana, 59802
-
Louisiana
- Cancer Care of Louisiana, New Orleans, Louisiana, 70115
-
Illinois
- Cancer Treatment Centers of America at Midwestern Regional Medical Center, Zion, Illinois, 60099
- Orchard Healthcare Research Inc., Skokie, Illinois, 60076
-
Tennessee
- Sarah Cannon Research Institution, Nashville, Tennessee, 37203
-
Alabama
- The University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, 35294
-
Ohio
- Oncology Hematology Care, Cincinnati, Ohio, 45242
-
Georgia
- Peachtree Hematology-Oncology Consultants PC, Atlanta, Georgia, 30318
- Georgia Cancer Specialists, Atlanta, Georgia, 30341
Powered by
SC CTSI